SRPT Sarepta Therapeutics Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
04:48
Aug 11
Aug 11
BTIG raises its price target on Spyre Therapeutics to 132 dollars from 112 dollars.
BTIG raises its price target on Spyre Therapeutics to 132 dollars from 112 dollars, reflecting an upward revision in analyst expectations.
23:15
Jul 27
Jul 27
Sarepta Therapeutics appoints former AbbVie executive Michael Severino as its new CEO to lead.
Sarepta Therapeutics appoints former AbbVie executive Michael Severino as its new CEO to lead the company through regulatory challenges.
09:40
Jul 20
Jul 20
Observes unexpected price action and sector uncertainty
Observes unexpected price action in the biotech stock, noting the inherent uncertainty in the sector.
LOW
17:37
Jul 18
Jul 18
SRPT could hit teens on FDA hold
Outlines a worst-case scenario for SRPT if the FDA upholds its clinical hold, projecting a realistic price in the low-to-mid teens.
MED
15:36
Jun 24
Jun 24
Conservative fair value well above current price
Author sees conservative fair value at $30 to $35, arguing the market is incorrectly pricing in a near worst-case scenario for the pipeline.
MED
18:00
Jun 23
Jun 23
SRPT PMO franchise yields excellent FCF
Highlights excellent gross and cash yields for the PMO franchise, though notes the corporation remains unprofitable due to gene therapy investments.
MED
13:45
Jun 16
Jun 16
Notes potential FDA cap on Elevidys
Notes a potential FDA cap on Elevidys could restrict access for older and non-ambulant patients.
MED
13:45
Jun 16
Jun 16
Notes Elevidys targets early ambulant patients
Observes the drug targets early ambulant patients with a one-time gene therapy.
LOW
10:17
Jun 15
Jun 15
Notes second death linked to Elevidys
Notes a second death linked to the Elevidys program.
MED
13:25
May 09
May 09
Cites criticism over weak Elevidys data
Cites criticism of SRPT's Elevidys for weak data, missed endpoints, and high costs.
MED
About SRPT Analyst Coverage
Buzzberg tracks SRPT (Sarepta Therapeutics) across 3 sources. 0 bullish vs 0 bearish calls from 3 analysts. Sentiment: evenly split. 10 total trade ideas tracked. Latest voices: FirstSquawk, Bloomberg, @MoodyWriter13.